![](/images/graphics-bg.png)
Does the Addition of Cetuximab to Radiochemotherapy Improve Outcome of Patients with Locally Advanced Rectal Cancer? Long-Term Results from Phase II Trials
Joint Authors
Kripp, M.
Horisberger, K.
Mai, S.
Kienle, P.
Gaiser, T.
Post, S.
Wenz, F.
Merx, K.
Hofheinz, R.-D.
Source
Gastroenterology Research and Practice
Issue
Vol. 2015, Issue 2015 (31 Dec. 2015), pp.1-8, 8 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2015-03-15
Country of Publication
Egypt
No. of Pages
8
Main Subjects
Abstract EN
Purpose.
The addition of cetuximab to radiochemotherapy (RCT) failed to improve complete response rates in locally advanced rectal cancer (LARC).
We report the long-term results in patients treated within two sequential clinical trials.
Methods.
Patients receiving neoadjuvant RCT using capecitabine and irinotecan (CapIri) within a phase I/II trial or CapIri + cetuximab within a phase II trial were evaluated for analysis of disease-free survival (DFS) and overall survival (OS).
KRAS exon 2 mutational status had been analyzed in patients receiving cetuximab.
Results.
37 patients from the CapIri trial and 49 patients from the CapIri-cetuximab treatment group were evaluable.
Median follow-up time was 75.2 months.
The 5-year DFS rate was 82% (CapIri) and 79% (CapIri-cetuximab) ( P = 0.62 ) .
The median OS was 127.4 months.
5-year OS was 73% for both groups (CapIri and CapIri-cetuximab) ( P = 0.61 ) .
No significant difference in DFS ( P = 0.86 ) or OS ( P = 0.39 ) was noticed between patients receiving CapIri and those receiving CapIri-cetuximab with KRAS wild-type tumors.
Conclusions.
As the addition of cetuximab did not improve neither DFS nor OS it should not play a role in the perioperative treatment of patients with LARC, not even of patients with (K)RAS WT tumors.
American Psychological Association (APA)
Kripp, M.& Horisberger, K.& Mai, S.& Kienle, P.& Gaiser, T.& Post, S.…[et al.]. 2015. Does the Addition of Cetuximab to Radiochemotherapy Improve Outcome of Patients with Locally Advanced Rectal Cancer? Long-Term Results from Phase II Trials. Gastroenterology Research and Practice،Vol. 2015, no. 2015, pp.1-8.
https://search.emarefa.net/detail/BIM-1063946
Modern Language Association (MLA)
Kripp, M.…[et al.]. Does the Addition of Cetuximab to Radiochemotherapy Improve Outcome of Patients with Locally Advanced Rectal Cancer? Long-Term Results from Phase II Trials. Gastroenterology Research and Practice No. 2015 (2015), pp.1-8.
https://search.emarefa.net/detail/BIM-1063946
American Medical Association (AMA)
Kripp, M.& Horisberger, K.& Mai, S.& Kienle, P.& Gaiser, T.& Post, S.…[et al.]. Does the Addition of Cetuximab to Radiochemotherapy Improve Outcome of Patients with Locally Advanced Rectal Cancer? Long-Term Results from Phase II Trials. Gastroenterology Research and Practice. 2015. Vol. 2015, no. 2015, pp.1-8.
https://search.emarefa.net/detail/BIM-1063946
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1063946